Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?The Zacks Style Score ...

BioMarin Pharmaceutical (BMRN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a c ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive est ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical (BMRN) reported adjusted earnings per share of 91 cents in third-quarter 2024, beating the Zacks Consensus Estimate of 78 cents. Quarterly earnings rose 98% year over year, driven by higher sales, partially offset by rising operating expenses. Total revenues were $746 million in the reported quarter, up 28% year over year on a reported basis and 32% on a constant-currency basis. Strong sales of Voxzogo drove this upside. The top line beat the Zacks Consensus Estimate of $707 million. ...

Financial Data and Key Metrics Changes - BioMarin reported record financial results with revenues reaching $746 million, a 28% increase compared to the same period in 2023 [5][19] - Non-GAAP diluted earnings per share increased nearly double compared to Q3 2023, totaling $0.91, while GAAP diluted earnings per share increased 162% to $0.55 [25][26] - Operating cash flows totaled $221 million in Q3, an increase of 63% compared to the same quarter last year [26][27] Business Line Data and Key Metrics Changes - VOXZOGO revenue grew 54% year-over-year, reaching $190 million in Q3, driven by new patient starts and expanded indications [8][19] - Enzyme Therapies portfolio generated $509 million in revenue, representing a 27% year-over-year increase, with ALDURAZYME being a significant contributor [20][13] - NAGLAZYME experienced a 21% year-over-year growth, while PALYNZIQ revenues increased 15% year-over-year [21][78] Market Data and Key Metrics Changes - The U.S. and EU markets comprise approximately 32% of the global total addressable patient population for achondroplasia, with 68% insulated from mid-term competitive threats [11][12] - BioMarin aims to expand VOXZOGO into more than 20 additional markets by 2027, with approximately 90% of the global achondroplasia patient population outside the U.S. [34] Company Strategy and Development Direction - The company is implementing a new corporate strategy focused on innovation, growth, and value commitment, structuring around new business units [6][30] - BioMarin is targeting approximately $4 billion in total revenues by 2027 and aims for a mid-teen compound annual growth rate for total revenues through 2034 [15][30] - The company plans to vigorously defend its intellectual property and leverage its global capabilities to maintain market leadership [12][62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the sustained leadership across the Skeletal Conditions franchise and the long-term growth potential of the Enzyme Therapies portfolio [9][13] - The company reaffirmed its long-term guidance despite increased competition, indicating that its initial guidance was not conservative [71][72] Other Important Information - BioMarin settled $495 million of convertible debt maturity in cash during Q3, retiring approximately 4 million potentially dilutive shares [27] - The company has a strong balance sheet with total cash and investments of approximately $1.5 billion at the end of Q3 2024 [27] Q&A Session Summary Question: What phase of development would be ideal for BioMarin at this stage in the pipeline's maturity? - Management indicated a focus on transactions less than $1.5 billion, leveraging their scientific capabilities and identifying earlier transactions to bolster research efforts [52][55] Question: Can you walk through the development strategy for BMN 333? - Management expressed excitement about BMN 333, highlighting its potential to increase pharmacokinetic exposure and efficacy in treating genetic skeletal disorders [58][60] Question: What is driving the increase in the ERT business growth? - The growth is primarily driven by PALYNZIQ, with strong patient uptake in the U.S. and new initiatives aimed at high-yield patient finding and geographic expansion [76][78] Question: Can you provide more color on the competitive positioning of PALYNZIQ? - Management believes the addition of new agents in the PKU space will benefit patients by providing more treatment options, and they are developing a next-generation PALYNZIQ [92][94] Question: What is the status of the transition to full approval for VOXZOGO? - Management is committed to measuring final adult height on patients from the pivotal study and is focused on converting to full approval [90][91]

BioMarin Pharmaceutical (BMRN) reported $745.74 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 28.3%. EPS of $0.91 for the same period compares to $0.46 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $706.95 million, representing a surprise of +5.49%. The company delivered an EPS surprise of +16.67%, with the consensus EPS estimate being $0.78. While investors scrutinize revenue and earnings changes year-over-year and how they ...

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.46 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 16.67%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.57 per share when it actually produced earnings of $0.96, delivering a surprise of 68.42%.Over the l ...

Third Quarter 2024 Earnings October 29, 2024 BiOMARIN® Table of Contents ● Business Overview & Highlights ● Q3 & YTD 2024 Key Financial Metrics ● Guidance & Outlook ● Non-GAAP Reconciliations 2 Forward-Looking Statements 3 3 This non-confidential presentation and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expe ...

Exhibit 99.1 Contact: Investors: Media: Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook Third Quarter 2024 Total Revenues of $746 million (+28% Y/Y and +32% at Constant Currency Y/Y); Year-to-date 2024 Total Revenues of $2.11 billion (+19% Y/Y and +23% at Constant Currency Y/Y) During the Quar ...